Edwards Lifesciences Corporation provides products and technologies to treat late-stage cardiovascular disease. The Company's products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals. Edwards Lifesciences Corporation is headquartered in Irvine, California.
Industry sector: Medical
Sector classification: Surgical appliances & supplies
Deep Learning based analysis and prediction model for Edwards Lifesciences Corporation (EW) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.
Model is in the production pipeline since Oct. 2, 2015.
Market data for EW model training are being downloaded from the
Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for EW.
Model is being retrained on a daily basis.
|% Held by Insiders||1.84%|
|% Held by Institutions||83.03%|
|EPS (last reported FY)||$3.80|
|EPS (last reported Q)||$1.22|
|EPS, estimated (last reported Q)||$1.10|
|Total revenues||$3 B|
|Net income||$1 B|